Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Nov 10, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Nov 7, 2025

Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst

Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline.

Seeking Alpha • Nov 8, 2025

Immunocore reports third quarter financial results and provides a business update

Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 160 mcg selected as the go-forward dose for brenetafusp in Phase 3 PRISM-MEL-301 trial, following Independent Data Monitoring Committee review Cash, cash equivalents and marketable securities of $892 million as of September 30, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

GlobeNewsWire • Nov 6, 2025

Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 6, 2025

Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Many stocks are objectively overvalued. That can make it difficult for investors to find opportunities for stocks with the potential to double.

MarketBeat • Oct 27, 2025

Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Immunocore Holdings plc (NASDAQ:IMCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Travis Coy - CFO, Executive VP & Head of Corporate Development Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, U.S. Head of SMID Cap Biotech Equity Research here at the firm.

Seeking Alpha • Sep 10, 2025

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robertson - Head of Investor Relations David Berman - Executive Vice President of Research Development Mohammed M. Dar - Senior VP of Clinical Development & Chief Medical Officer Ralph Torbay - Corporate Participant EVP of Commercial - Corporate Participant Travis A.

Seeking Alpha • Aug 9, 2025

Immunocore (IMCR) Q2 Revenue Jumps 30%

Immunocore Plc (IMCR 0.06%), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increase, with $98.0 million (GAAP) surpassing consensus estimates of $92.15 million.

The Motley Fool • Aug 7, 2025

Immunocore reports second quarter financial results and provides a business update

KIMMTRAK ® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year

GlobeNewsWire • Aug 7, 2025